Home > Insider Trading > Filing (0000947871-11-000447)

Filing Details

Accession Number:: 0000947871-11-000447
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-04-29 21:14:25
Reporting Period:: 2011-04-11

Filing Date:: 2011-04-29
Accepted Time:: 2011-04-29 21:14:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1368148	Athersys Inc / New	ATHX	Pharmaceutical Preparations (2834)	204864095

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1055949	D Samuel Isaly	767 3Rd Avenue, 30Th Floor New York NY 10017	No	No	Yes	No
1055951	Orbimed Advisors Llc	767 3Rd Avenue, 30Th Floor New York NY 10017	No	No	Yes	No
1432241	Orbimed Capital Gp Iii Llc	767 3Rd Avenue, 30Th Floor New York NY 10017	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2011-04-11	12,900	$2.91	1,775,200	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2011-04-11	100	$2.91	16,900	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2011-04-12	14,200	$2.90	1,761,000	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2011-04-12	100	$2.90	16,800	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2011-04-13	47,200	$2.94	1,713,800	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2011-04-13	500	$2.94	16,300	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2011-04-14	20,700	$2.91	1,693,100	No	4	S	Indirect	See Foonotes
Common Stock	Disposition	2011-04-14	200	$2.91	16,100	No	4	S	Indirect	See Foonote
Common Stock	Disposition	2011-04-15	29,900	$2.90	1,663,200	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2011-04-15	300	$2.90	15,800	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2011-04-18	15,600	$2.93	1,647,600	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2011-04-18	100	$2.93	15,700	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2011-04-20	1,300	$2.90	1,646,300	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2011-04-21	1,975	$2.90	1,644,325	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2011-04-21	25	$2.90	15,675	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2011-04-25	36,250	$2.90	1,608,075	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2011-04-25	350	$2.90	15,325	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2011-04-26	7,625	$2.90	1,600,450	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2011-04-26	75	$2.90	15,250	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Foonotes
No	4	S	Indirect	See Foonote
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnote

Footnotes

These Shares are directly owned by OrbiMed Private Investments III, LP ("OPI III") and may be deemed to be indirectly beneficially owned by OrbiMed Capital GP III LLC ("Capital"), OrbiMed Advisors LLC ("Advisors") and Samuel D. Isaly ("Isaly"). Capital is the sole general partner of OPI III. Advisors, a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of Capital. Pursuant to those relationships, Capital and Advisors have discretionary investment management authority with respect to the assets of OPI III. Such authority includes the power to vote and otherwise dispose of securities held by OPI III.
Isaly, a natural person, is the managing member of, and holder of a controlling interest, in Advisors. In such capacity, Isaly may also be deemed to have investment and voting power over the Shares held by OPI III. As a result, each of Capital, Advisors and Isaly may be deemed to have beneficial ownership of the Shares held by OPI III.
This report on Form 4 is jointly filed by Capital, Advisors and Isaly. Each of the reporting persons disclaims beneficial ownership of the Shares reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting persons are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.
These Shares are directly owned by OrbiMed Associates III, LP ("Associates") and may be deemed to be indirectly beneficially owned by Advisors and Isaly. Advisors is the sole general partner of Associates. Pursuant to that relationship, Advisors has discretionary investment management authority with respect to the assets of Associates. Such authority includes the power to vote and otherwise dispose of securities held by Associates. Isaly, in his capacity as the managing member of, and holder of a controlling interest, in Advisors, may also be deemed to have voting and investment power over the Shares held by Associates. As a result, each of Advisors and Isaly may be deemed to have beneficial ownership of the Shares held by Associates.
The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $2.91 to $2.92, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $2.90 to $2.94, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $2.90 to $2.97, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $2.90 to $2.93, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $2.90 to $2.91, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $2.90 to $2.92, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $2.88 to $2.90, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in this footnote.